Results 1 to 10 of about 5,055 (142)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones [PDF]

Journal of Hematology and Oncology, 2016
Background Acute myeloid leukemia (AML) is a heterogeneous clonal disorder presenting with accumulation of proliferating undifferentiated blasts. Xenograft transplantation studies have demonstrated a rare population of leukemia-initiating cells called ...
Adhra Al-Mawali
exaly   +7 more sources

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia [PDF]

Proteomes, 2018
Targeting of leukemic stem cells with specific immunotherapy would be an ideal approach for the treatment of myeloid malignancies, but suitable epitopes are unknown.
Johannes Schmidt, Johannes Schetelig, Martin Bornhauser   +2 more
exaly   +5 more sources

Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis [PDF]

Frontiers in Pediatrics
IntroductionAcute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes ...
Zheng Li, Qinfa Chen, Zhiyong Zhou, Fei He   +3 more
doaj   +2 more sources

CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection. [PDF]

Acta Haematol, 2017
<b><i>Background/Aims:</i></b> In CD34-positive acute myeloid leukaemia (AML), the leukaemia-initiating event likely takes place in the CD34+CD38- cell compartment. CD123 has been shown to be a unique marker of leukaemic stem cells within the CD34+CD38- compartment.
Al-Mawali A, Pinto AD, Al-Zadjali S.
europepmc   +3 more sources

Distinct Expression Patterns of CD123 and CD34 on Normal Bone Marrow B-Cell Precursors (“Hematogones”) and B Lymphoblastic Leukemia Blasts [PDF]

American Journal of Clinical Pathology, 2009
We compared the expression of CD123, the alpha chain of the interleukin-3 receptor, on normal B-cell precursors in bone marrow ("hematogones") from 75 specimens and on leukemic blasts in 45 newly diagnosed B-acute lymphoblastic leukemias (B-ALL) cases.
Patrick J Buckley, Anand S Lagoo
exaly   +3 more sources

High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study

Haematologica, 2011
Background Acute myeloid leukemias arise from a rare population of leukemic cells, known as leukemic stem cells, which initiate the disease and contribute to frequent relapses. Although the phenotype of these cells remains unclear in most patients, these
François Vergez, Alexa S. Green, Jerome Tamburini, Jean-Emmanuel Sarry, Baptiste Gaillard, Pascale Cornillet-Lefebvre, Melanie Pannetier, Aymeric Neyret, Nicolas Chapuis, Norbert Ifrah, François Dreyfus, Stéphane Manenti, Cecile Demur, Eric Delabesse, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Christian Recher, Valerie Bardet   +18 more
doaj   +4 more sources

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

Haematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Amber Gordon, Donna Bucci, David M. Lucas, Alice Mims, Christopher Brooks, Adrienne Dorrance, Alison Walker, William Blum, John C. Byrd, Gerard Lozanski, Sumithira Vasu, Natarajan Muthusamy   +18 more
doaj   +4 more sources

Refined detection of CD34⁺CD38⁻CD45RA⁺ leukemic stem cells using a single-tube flow cytometry assay and its strong association with measurable residual disease in acute myeloid leukemia: a retrospective cohort study [PDF]

Stem Cell Research & Therapy
Background Leukemic stem cells (LSCs) are the cellular reservoir most strongly implicated in relapse of acute myeloid leukemia, yet their operational detection by multiparameter flow cytometry remains challenging because of immunophenotypic overlap with ...
Amir Abbas Navidinia, Shahrbanoo Rostami, Najibe Karami, Mohammadreza Shemshadinia, Habibeh Sabri Patekhor, Akram Hajaliaskari, Saeed Mohammadi, Tahereh Rostami, Maryam Barkhordar, Mohammad Vaezi, Ghasem Janbabaei, Bahram Chahardouli   +11 more
doaj   +2 more sources

CD34⁺CD38^-CD123⁺ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. [PDF]

Cancers (Basel), 2020
The prognostic impact of immunophenotypic CD34+CD38−CD123+ leukemic stem cell (iLSC) frequency at diagnosis has been demonstrated in younger patients treated by intensive chemotherapy, however, this is less clear in older patients. Furthermore, the impact of iLSC in patients treated by hypomethylating agents is unknown.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C.   +13 more
europepmc   +5 more sources

Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy

Iraqi Journal of Hematology, 2016
Background: Leukemic stem cells (LSCs) are thought to originate either from normal hematopoietic stem cells or from more differentiated progenitor cells.
Haidar H Al-Fatlawi, Raad Jaber Musa
doaj   +2 more sources